Skip to main content

Cingulate Inc. (CING) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $5.36 (+4.08%)

Consensus Target
$11.00
Upside
+105.2%
Analysts
4
Rating
Buy(2.00)

Price Target Range

Low $11.00High $11.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
May 19, 2025Boobalan PachaiyappanRoth Capital$11.00+105.2%

CING vs Sector & Market

MetricCINGHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count4818
Target Upside+105.2%+1150.1%+14.9%
P/E Ratio-1.136.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$1M$2M$4M3
2027-12-31$2M$7M$12M4
2028-12-31$10M$21M$36M2
2029-12-31$20M$44M$75M1
2030-12-31$32M$70M$120M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-3.05$-1.92$-1.464
2027-12-31$-2.82$-1.47$-0.424
2028-12-31$-1.08$-0.56$-0.161
2029-12-31$0.34$1.16$2.231
2030-12-31$0.88$3.00$5.761

Frequently Asked Questions

What is the analyst consensus for CING?

The consensus among 4 analysts covering Cingulate Inc. (CING) is Buy with an average price target of $11.00.

What is the highest price target for CING?

The highest price target for CING is $11.00, set by Boobalan Pachaiyappan at Roth Capital on 2025-05-19.

What is the lowest price target for CING?

The lowest price target for CING is $11.00, set by Boobalan Pachaiyappan at Roth Capital on 2025-05-19.

How many analysts cover CING?

4 analysts have issued ratings for Cingulate Inc. in the past 12 months.

Is CING a buy or sell right now?

Based on 4 analyst ratings, CING has a consensus rating of Buy (2.00/5) with a +105.2% upside to the consensus target of $11.00.

What are the earnings estimates for CING?

Analysts estimate CING will report EPS of $-1.92 for the period ending 2026-12-31, with revenue estimated at $2M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.